drugset / Trial / NCT04301778
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Phase 2
Completed
5 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca · collabSyndax Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The purposed of this research is to study the safety and clinical activity of the combination of durvalumab and a CSF-1R inhibitor (SNDX-6352) in people with Intrahepatic Cholangiocarcinoma.
Timeline
- Start
- 2021-08-24
- Primary completion
- 2022-11-04
- Completion
- 2024-02-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axatilimab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |